A Phase II Study of SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx
Conditions: SBRT Interventions: Combination Product: SBRT+chemoimmunotherapy Sponsors: Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Docetaxel | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Oral Cancer | Oropharyngeal Cancer | Research | Study | Taxotere